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Abstract
Background: Flavonoids are abundant plant phenolic compounds. More than 6000 have been
identified to date, and some have been shown to possess antiparasitic activity. Here we investigate
the effects of a range of common dietary flavonoids on the growth of two strains of the human
malaria parasite Plasmodium falciparum.
Findings: A chloroquine-sensitive (3D7) and a chloroquine-resistant (7G8) strain of P. falciparum
were tested for in vitro susceptibility to a range of individual dietary flavonoids and flavonoid
combinations. Parasite susceptibility was measured in 96-well plates over 96 h using a previously
described [3H]hypoxanthine incorporation assay. Of the eleven flavonoids tested, eight showed
antiplasmodial activity against the 3D7 strain (with IC50 values between 11 and 66 M), and all
showed activity against the 7G8 strain (with IC50 values between 12 and 76 M). The most active
compound against both strains was luteolin, with IC50 values of 11 ± 1 M and 12 ± 1 M for 3D7
and 7G8, respectively. Luteolin was found to prevent the progression of parasite growth beyond
the young trophozoite stage, and did not affect parasite susceptibility to the antimalarial drugs
chloroquine or artemisinin. Combining low concentrations of flavonoids was found to produce an
apparent additive antiplasmodial effect.
Conclusion: Certain common dietary flavonoids inhibit the intraerythrocytic growth of the 3D7
and 7G8 strains of P. falciparum. Flavonoid combinations warrant further investigation as
antiplasmodial agents.
Findings
Flavonoids are ubiquitous plant phenolic compounds
that consist of two aromatic rings linked by a three-carbon
bridge (see Table 1 for structure). More than 6000 flavo-
noids have been identified to date, and their essential
functions in plants include regulating growth and provid-
ing protection against pathogens (reviewed in [1]). They
are currently attracting significant medical interest
because of their antioxidant, antitumor, antiinflamma-
tory, antimicrobial and antiviral activities. Flavonoids are
present in fruits, vegetables, wine, tea and coffee. Esti-
mates of the daily intake of flavonoids in developed coun-
tries are as high as 1–2 g [1].
A number of reports have demonstrated growth inhibi-
tory effects of flavonoids, particularly of the flavonol
quercetin and of the flavone luteolin, on the protozoan
parasite genera Toxoplasma [2], Trypanosoma [3] and Leish-
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and malaria describe the antiplasmodial activity-guided
fractionation of plants (including species used in tradi-
tional medicine). Flavonoids (usually along with other
compounds) have been identified in the antiplasmodial
fractions of many plants, and in some cases have been
shown to possess antiplasmodial activity when isolated
[4,7-12]. Despite this, until very recently only the structur-
ally distinct chalcone subclass of flavonoids attracted
much further investigation.
In this study, the flavanone naringenin, the isoflavone
genistein, and a range of flavonols (kaempferol, myrice-
tin, quercetin and isoquercitrin) and flavones (acacetin,
apigenin, baicalein, chrysin and luteolin) were tested
against a chloroquine-sensitive (3D7) and a chloroquine-
resistant (7G8) strain of Plasmodium falciparum. The flavo-
noids were purchased from Sigma-Aldrich (Australia),
and purities were  95% except for isoquercitrin which
was  90%. A recent study demonstrated the in vitro
antiplasmodial activities of a number of these compounds
[13]; we confirm and extend these findings with different
P. falciparum strains.
Of the eleven flavonoids tested, eight showed antiplasmo-
dial activity against the 3D7 strain, with mean IC50 values
in the range 11–66 M (Table 1). The remaining three
(acacetin, naringenin and genistein) did not achieve 50%
parasite killing at the highest concentrations tested (which
varied according to solubility in aqueous media; DMSO
concentrations were kept  0.1% to prevent any effect on
parasite growth). All the flavonoids tested showed meas-
urable activity against the chloroquine-resistant 7G8
strain, with IC50 values between 12 and 76 M. The most
Table 1: Flavonoid IC50 values for growth inhibition of P. falciparum 
Class Major food sources 
[17]
Flavonoid Chemical 
substitutions/
modifications
In vitro antiplasmodial activity (IC50, M)a
LogD (pH 7.0)b
3D7 7G8
Flavonols Onions, kale, broccoli, 
apples, cherries, 
fennel, sorrel, berries, 
tea
Kaempferol 3, 5, 7, 4' – OH 33 ± 7 25 ± 2 2.40
Myricetin 3, 5, 7, 3', 4', 5' – OH 40 ± 10 76 ± 23 2.06
Quercetin 3, 5, 7, 3', 4' – OH 15 ± 5 14 ± 1 2.09
Isoquercitrin 3-gluc, 5, 7, 3', 4' – 
OH
66 ± 10 66 ± 18 1.59
Flavones Parsley, thyme, celery, 
sweet red pepper
Acacetin 5, 7 – OH 4' – OCH3 > 100 13 ± 2 2.77
Apigenin 5, 7, 4' – OH 20 ± 3 13 ± 2 2.77
Baicalein 5, 6, 7 – OH 32 ± 1 21 ± 6 3.18
Chrysin 5, 7 – OH 18 ± 3 22 ± 4 2.79
Luteolin 5, 7, 3', 4' – OH 11 ± 1 12 ± 1 2.62
Flavanones Citrus fruits, prunes Naringenin 5, 7, 4' – OH, single 
bond between 2 and 3
> 125 71 ± 10 2.17
Isoflavones Legumes Genistein 5, 7, 4' – OH, B ring 
attached to 3
> 50 29 ± 5 1.53
Chloroquine NA NA NA 0.006 ± 0.0003 0.084 ± 0.026 ND
a Values are the means (± S.E.M.) of results from three independent experiments, each performed in duplicate or triplicate. Parasite susceptibility was 
measured in 96-well plates over 96 h using the [3H]hypoxanthine incorporation assay [19]. b LogD (the octanol-water distribution coefficient) was 
predicted using PrologD (Pallas for Windows version 2.1, CompuDrug International Inc.). Good cell permeability requires a logD value of 2–5 [20]. 
NA, not applicable; ND, not determined.
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values of 11 ± 1 M and 12 ± 1 M for 3D7 and 7G8,
respectively (Table 1).
Marked differences in the susceptibilities of the two
strains to some flavonoids (most notably to acacetin)
were observed in this study and in that of Tasdemir et al.
[13]. In both studies, the chloroquine-resistant strain was
generally more susceptible to growth inhibition. Whether
enhanced sensitivity to some flavonoids relates to the
chloroquine resistance phenotype or other difference(s)
in genetic background is not known. These strain differ-
ences make structure-activity determinations difficult.
Furthermore, potential differences in cell permeability
should also be considered. The higher antiplasmodial
activity of quercetin (logD 2.09) compared to the querce-
tin glucoside isoquercitrin (logD 1.59) (P = 0.002, paired
t-test) could be a result of better cell permeability. Simi-
larly, the flavanone naringenin (logD 2.17) differs from
apigenin (logD 2.77) only in the absence of a double
bond in the C ring but is much less active (P = 0.02, paired
t-test for 7G8). Also, the isoflavone genistein (logD 1.53)
differs from apigenin (logD 2.77) only in that the B ring
is attached to carbon 3 of the C ring rather than carbon 2,
and is less active against both strains (P = 0.03, paired t-
test for 7G8). However, the testing of a number of addi-
tional flavonoids would be required to conclude that dif-
ferences in activities are a result of different cell
permeabilities.
The effect of a number of the flavonoids tested here on the
viability of two normal (non-cancerous) human cell lines
has been reported [14]. In the cases of apigenin, kaemp-
ferol, luteolin and quercetin, the IC50 values against both
strains of P. falciparum are at least 4-fold lower than the
IC50 values reported against both human cell lines. Narin-
genin has relatively low activity against P. falciparum
(Table 1) and human cells [14]. In addition, Mamani-
Matsuda et al. [3] investigated quercetin toxicity towards
haemopoietic cells and found that the IC50 value was
greater than 100 M (> 6-fold higher than the IC50 against
P. falciparum reported here; Table 1).
To investigate which stage of the parasite's intraerythro-
cytic lifecycle is inhibited by flavonoids, we prepared
Giemsa-stained 7G8-infected erythrocyte smears at vari-
ous time points following the addition of 20 M luteolin
(~2 × IC50). Figure 1 reveals that luteolin does not inhibit
the ring stage of the parasite but prevents the progression
The effect of luteolin on the intraerythrocytic growth of P. falciparumFigure 1
The effect of luteolin on the intraerythrocytic growth of P. falciparum. Giemsa-stained smears were prepared at 0, 
19, 26 and 48 h after the addition of luteolin (20 M) dissolved in DMSO or an equal volume of DMSO (control; 0.025% 
DMSO) to 7G8-infected erythrocytes (1% parasitemia, 2% hematocrit). While control parasites developed into mature tro-
phozoites (26 h) that subsequently gave rise to daughter parasites (48 h), the growth of luteolin-treated parasites was arrested 
at the young trophozoite stage. Luteolin-treated parasites did not give rise to daughter parasites, resulting in a reduced para-
sitemia compared to the control at the 48 h time point.Page 3 of 5
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The parasites are therefore unable to complete a full
intraerythrocytic cycle. An arrest in cell cycle progression
has also been observed for Leishmania donovani promastig-
otes treated with luteolin or quercetin [5]. Furthermore,
quercetin has been shown to inhibit bradyzoite develop-
ment in Toxoplasma gondii [2]. Further studies are required
to elucidate the mechanism by which flavonoids arrest
parasite growth.
There have been several reports of flavonoids showing
synergistic or antagonistic activities with various antipara-
sitic drugs [10,15,16]. We therefore tested the effect of
luteolin (at concentrations of 2.5 M, 5 M, 10 M and 20
M) on the susceptibility of 7G8 to two important anti-
malarial drugs, chloroquine and artemisinin. Luteolin did
not significantly affect the IC50 values of either drug (not
shown). Therefore, luteolin should not antagonise the
activities of chloroquine or artemisinin if used in combi-
nation therapy.
The finding that common dietary compounds display
antiplasmodial activity raises the intriguing question of
whether a plant-based diet could play a role in malaria
prevention or lessen disease severity. To investigate
whether combinations of dietary flavonoids could display
an additive effect, we combined equimolar amounts of
the eleven flavonoids tested in this study such that the
highest concentration of each was not toxic to the parasite
(4 M). This resulted in 50% growth inhibition against
7G8 at a total flavonoid concentration of 31 ± 3 M (Fig-
ure 2A), a value similar to the mean IC50 value for the
eleven flavonoids (33 M). At this total flavonoid concen-
tration, each individual flavonoid is present at a concen-
tration of only 2.8 M. We then combined equimolar
amounts of three of the most active compounds, luteolin,
quercetin and apigenin, such that the highest total flavo-
noid concentration was 44 M (i.e. the same maximum
total flavonoid concentration used when 11 flavonoids
were combined). The combination of these three flavo-
noids gave an IC50 value of 21 ± 2 M (Figure 2B), some-
what higher than their mean IC50 value (13 M).
However, at this total flavonoid concentration each indi-
vidual flavonoid is only present at a concentration of 7
M, which is lower than individual IC50 values. Adding a
less active flavonoid (naringenin) to this combination,
while maintaining the same maximum combined flavo-
noid concentration of 44 M (i.e. each individual flavo-
noid was now present at a maximum concentration of 11
M), increased the IC50 value close to the new mean value
(combination IC50 = 24 ± 2 M, average IC50 = 28 M; Fig-
ure 2C). While the data are consistent with the flavonoids
having an additive antiplasmodial effect, the possibility
that there is a combination of synergistic and antagonistic
effects between some of the individual flavonoids in these
combinations that results in an apparent additive effect
cannot be excluded.
The concentrations of diet-derived individual flavonoids
in plasma are unlikely to reach those required for com-
plete parasite killing. The extent to which flavonoids are
absorbed from the gastrointestinal tract depends on fac-
tors such as the flavonoid itself and the dietary source
[1,17,18]. Another important issue is the metabolism of
flavonoids in vivo to form potentially less active conju-
gates [18]. Thus, it will be important to investigate the
The effects of flavonoid combinations on the proliferation of the 7G8 strain of P. falciparumFigure 2
The effects of flavonoid combinations on the proliferation of the 7G8 strain of P. falciparum. Equimolar amounts of 
(A) the eleven flavonoids tested in this study, (B) apigenin, luteolin and quercetin, and (C) apigenin, luteolin, naringenin and 
quercetin, were combined. The data are averaged from three independent experiments, each performed in duplicate or tripli-
cate. Error bars represent S.E.M. 
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activities of the main conjugates of promising antiplasmo-
dial flavonoids. Nevertheless, our study raises the possi-
bility of using clinically relevant, non-toxic
concentrations of flavonoid combinations as antiplasmo-
dial agents.
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